Featured Research

from universities, journals, and other organizations

NIAID Describes Challenges, Prospects For An HIV Vaccine

Date:
August 29, 2008
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Events of the past year in HIV vaccine research have led some to question whether an effective HIV vaccine will ever be developed. In the Aug. 28 edition of the New England Journal of Medicine, officials from NIAID examine the extraordinarily challenging properties of the virus that have made a vaccine elusive and outline the scientific questions that, if answered, could lead to an effective HIV vaccine.

Events of the past year in HIV vaccine research have led some to question whether an effective HIV vaccine will ever be developed. In the August 28 edition of the New England Journal of Medicine, officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine the extraordinarily challenging properties of the virus that have made a vaccine elusive and outline the scientific questions that, if answered, could lead to an effective HIV vaccine.

In recent years, the most extensively studied HIV vaccines have aimed to mobilize immune cells called T cells, write Anthony S. Fauci, M.D., NIAID director, and Margaret I. Johnston, Ph.D., director of the Vaccine Research Program in NIAID's Division of AIDS.

T-cell vaccines are not expected to prevent HIV infection. Rather, they could potentially reduce the level of virus (but not eliminate it) following infection, limit the number of immune cells that HIV destroys, and thus delay the progression to AIDS. There is no evidence yet that T-cell HIV vaccines work in humans, however.

If the vaccines ultimately do, their effectiveness may vary greatly depending on the genetic make-up of each individual, given that T-cell immunity is dependent on genetic factors. Furthermore, because the virus would persist in the blood of vaccinated individuals, T-cell vaccines would likely generate only transient "herd immunity"--that is, population-wide protection from disease conferred by vaccination of a percentage of the community.

In response to the failure last September of a T-cell vaccine for which many people had high hopes, the HIV vaccine field has undergone a self-reexamination and has determined that the balance between fundamental discovery research and product development should shift toward discovery. In particular, future research must intensify the study of broadly neutralizing antibodies to HIV, why most HIV-infected people do not make them, and the design of novel strategies to induce them with a vaccine.

Also, studying the earliest stages of HIV infection may shed light on ways to manipulate innate and mucosal immune responses to widen the window of opportunity for viral eradication, to prevent the virus from advancing to gut-associated lymphoid tissue, or both.

The authors conclude with cautious optimism that an effective HIV vaccine will be developed, but will depend on the significant growth of scientific understanding of HIV disease and human responses to the virus.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. MI Johnston and AS Fauci. An HIV vaccine--challenges and prospects. New England Journal of Medicine, 2008; DOI: 10.1056/NEJMp0806162

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "NIAID Describes Challenges, Prospects For An HIV Vaccine." ScienceDaily. ScienceDaily, 29 August 2008. <www.sciencedaily.com/releases/2008/08/080827195736.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2008, August 29). NIAID Describes Challenges, Prospects For An HIV Vaccine. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2008/08/080827195736.htm
NIH/National Institute of Allergy and Infectious Diseases. "NIAID Describes Challenges, Prospects For An HIV Vaccine." ScienceDaily. www.sciencedaily.com/releases/2008/08/080827195736.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins